Mid
G
GMABAI Stock Diagnostic Report
Genmab reports trial results for ovarian cancer drug candidate
Genmab announced clinical trial results for an ovarian cancer drug candidate, but without specific details, the stock impact is assessed as neutral.
View Source Article ↗
AI CATALYST SCORE50 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+ANALYSIS HISTORY
GMAB Analysis History (Last 30 Days)